A new immune-modulating treatment has shown promising results for treating moderate to severe eczema, delivering fast itch ...

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced the initiation of two new clinical trials to investigate the efficacy and safety of nemolizumab in treating patients ...

The agency said it will evaluate whether further regulatory action is needed after investigating the deaths of two patients ...

New research suggests the lack of a bacterium known to help infants digest breast milk could have significant consequences ...

NKTR stock is up around 150% in today’s trading session following the recently announced positive results from its Phase 2b ...

Shares of Nektar Therapeutics (NKTR) more than doubled on Tuesday afternoon after the company announced that its mid-stage ...

US biotech Nektar Therapeutics experienced a remarkable 130% increase in its share price, which reached $21.9, as it reported ...

USA: Researchers have discovered in a new study that young children with moderate-to-severe atopic dermatitis (AD) tend to be ...

Breakthrough study could lead to new treatments as experts explore how skin fungi trigger debilitating skin condition ...

Nektar Therapeutics (NASDAQ:NKTR) saw its stock soar 140% following promising Phase 2b trial results for its experimental treatment rezpegaldesleukin in moderate-to-severe atopic dermatitis. The ...

Nektar reported positive Phase 2b trial data for rezpegaldesleukin in atopic dermatitis, showing strong efficacy and a ...

Nektar Therapeutics is enjoying the sweet taste of clinical trial success after years of swallowing bitter pills. | Nektar Therapeutics is enjoying the sweet taste of clinical trial success after ...